TNYA240517C2500
- 2.10
- 0.000.00%
Tenaya Therapeutics Newsroom
TD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)
Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating
Tenaya Therapeutics (TNYA) has an average rating of buy and price targets ranging from $7 to $40, according to analysts polled by Capital IQ. Price: 4.26, Change: +0.01, Percent Change: +0.24
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Buy Rating Affirmed for Tenaya Therapeutics Amidst Promising Gene Therapy Advances
Maintaining a Buy Rating for Tenaya Therapeutics: A Comprehensive Financial and Pipeline Progress Analysis
Buy Rating Affirmed for Tenaya Therapeutics on Strong Program Prospects and Financial Stability
Express News | HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Tenaya Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 294.74% HC Wainwright & Co. → $18 Reiterates Buy → Buy 03/21/2024 338.6% Chardan Capital → $20
Tenaya Therapeutics (TNYA) Gets a Buy From Piper Sandler
Tenaya Therapeutics GAAP EPS of -$0.40 Beats by $0.02
Tenaya Therapeutics: A Strong Buy on Financial Stability and Advancing Gene Therapy Programs
Express News | Tenaya Therapeutics Inc: Cost Containment Measures Including Committed Plan to Reduce Workforce by About 22%, Sees to Be Completed During Q2
Tenaya Therapeutics Cutting Workforce by 22%
By Paul Ziobro Tenaya Therapeutics is reducing its workforce by about 22%, as it looks to cut costs and focus on clinical trials for heart-disease therapies. The South San Francisco, Calif.-based bi
Express News | Tenaya Therapeutics- Expects Current Cash, Cash Equivalents and Investments in Marketable Securities to Be Sufficient to Fund Co Into H2 of 2025
Express News | Tenaya Therapeutics Inc - as of March 31, 2024, Cash, Cash Equivalents and Investments in Marketable Securities Were $122.2 Million
Tenaya Therapeutics | 10-Q: Quarterly report
Express News | Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Tenaya Therapeutics Q1 Operating Income USD -33.762 Million
Express News | Tenaya Therapeutics Q1 Pretax Profit USD -32.228 Million Vs. Ibes Estimate USD -33.4 Million
Express News | Tenaya Therapeutics Q1 Basic EPS USD -0.4